Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4152120 | 0.90 | CASR (0.66) | CASRNR1I2 | |
| SCHEMBL4157957 | 0.86 | CASR (0.69) | CASRNR1I2 | |
| SCHEMBL4142604 | 0.84 | CASR (0.69) | CASRNR1I2 | |
| SCHEMBL3379098 | 0.82 | CASR (1.00) | CASRNR1I2 | |
| SCHEMBL4148580 | 0.81 | CASR (0.62) | CASR | |
| SCHEMBL13851568 | 0.80 | CASR (0.52) | CASRNR1I2 | |
| SCHEMBL4143241 | 0.80 | CASR (0.74) | CASRNR1I2 | |
| SCHEMBL4151289 | 0.80 | CASR (0.82) | CASRNR1I2 | |
| SCHEMBL4140088 | 0.80 | CASR (0.78) | CASRNR1I2 | |
| SCHEMBL4138103 | 0.80 | CASR (0.78) | CASRNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | claimed |
| EP-1951244-A2 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | claimed |
| WO-2007062370-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | claimed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| CN-101360498-A | Calcilytic compounds | SMITHKLINE BEECHAM CORP (US) | 2009-02-04 | — | — | CN | disclosed |
| WO-2007062370-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | CALCR, SOST, CALCB | CASR 12/4885NR1I2 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.